UK markets open in 4 hours 48 minutes

FibroGen, Inc. (FGEN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.1600+0.0200 (+1.75%)
At close: 04:00PM EDT
1.4200 +0.26 (+22.41%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.1400
Open1.2000
Bid1.1300 x 100
Ask1.2000 x 100
Day's range1.1500 - 1.2600
52-week range0.3330 - 19.4700
Volume1,323,254
Avg. volume1,876,841
Market cap115.39M
Beta (5Y monthly)0.74
PE ratio (TTM)N/A
EPS (TTM)-2.9700
Earnings date05 Aug 2024 - 09 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.75
  • GlobeNewswire

    FibroGen Reports First Quarter 2024 Financial Results

    Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer anticipated in mid-2024Topline data from LAPIS Phase 3 study in locally advanced unresectable pancreatic cancer anticipated in 3Q 2024Reported compelling data from Phase 1 monotherapy study of FG-3246, a CD46 targeted antibody drug conjugate, in metastatic castration-resistant prostate cancer First quarter net revenue growth of 55% year over year, driven by roxadust

  • GlobeNewswire

    FibroGen to Report First Quarter 2024 Financial Results

    SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the

  • GlobeNewswire

    FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

    SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois. Details for the poster presentation are as foll